Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Expands By 604.6%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 214,200 shares, an increase of 604.6% from the March 31st total of 30,400 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 0.2 days.

Sonoma Pharmaceuticals Stock Performance

Sonoma Pharmaceuticals stock remained flat at $0.16 on Thursday. The company’s stock had a trading volume of 112,297 shares, compared to its average volume of 1,619,034. The company’s fifty day moving average is $0.15 and its two-hundred day moving average is $0.21. The stock has a market capitalization of $2.50 million, a P/E ratio of -0.17 and a beta of 1.28. Sonoma Pharmaceuticals has a one year low of $0.12 and a one year high of $1.52.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Thursday, February 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The business had revenue of $3.14 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 41.24% and a negative return on equity of 58.93%. As a group, equities research analysts forecast that Sonoma Pharmaceuticals will post -0.89 earnings per share for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.